Evidence map›Paper›PMID 35130878›Full record

ArticleBMC medicine2022

Lifetime risk of cardiovascular-renal disease in type 2 diabetes: a population-based study in 473,399 individuals.

Ruiqi Zhang, Jil Billy Mamza, Tamsin Morris, George Godfrey, Folkert W Asselbergs, Spiros Denaxas, Harry Hemingway, Amitava Banerjee

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 35 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Ruiqi ZhangRobertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
Jil Billy MamzaMedical and Scientific Affairs, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Tamsin MorrisMedical and Scientific Affairs, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
George GodfreyMedical and Scientific Affairs, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Folkert W AsselbergsInstitute of Health Informatics, University College London, London, UK.
Spiros DenaxasInstitute of Health Informatics, University College London, London, UK.
Harry HemingwayInstitute of Health Informatics, University College London, London, UK.
Amitava BanerjeeInstitute of Health Informatics, University College London, London, UK. ami.banerjee@ucl.ac.uk.ORCID http://orcid.org/0000-0001-8741-3411
AstraZeneca (United Kingdom) · GBUniversity of London · GBUniversity College Hospital · GBUtrecht University · NL

Funding

Medical Research Council G0902393Medical Research Council MC_PC_13041Medical Research Council MR/K006584/1
6 · The paper itself

Abstract

backgroundCardiovascular and renal diseases (CVRD) are major causes of mortality in individuals with type 2 diabetes (T2D). Studies of lifetime risk have neither considered all CVRD together nor the relative contribution of major risk factors to combined disease burden.

methodsIn a population-based cohort study using national electronic health records, we studied 473,399 individuals with T2D in England 2007-2018. Lifetime risk of individual and combined major adverse renal cardiovascular events, MARCE (including CV death and CVRD: heart failure; chronic kidney disease; myocardial infarction; stroke or peripheral artery disease), were estimated, accounting for baseline CVRD status and competing risk of death. We calculated population attributable risk for individual CVRD components. Ideal cardiovascular health was defined by blood pressure, cholesterol, glucose, smoking, physical activity, diet, and body mass index (i.e. modifiable risk factors).

resultsIn individuals with T2D, lifetime risk of MARCE was 80% in those free from CVRD and was 97%, 93%, 98%, 89% and 91% in individuals with heart failure, chronic kidney disease, myocardial infarction, stroke and peripheral arterial disease, respectively at baseline. Among CVRD-free individuals, lifetime risk of chronic kidney disease was highest (54%), followed by CV death (41%), heart failure (29%), stroke (20%), myocardial infarction (19%) and peripheral arterial disease (9%). In those with HF only, 75% of MARCE after index T2D can be attributed to HF after adjusting for age, gender, and comorbidities. Compared with those with > 1, < 3 and ≥3 modifiable health risk behaviours, achieving ideal cardiovascular health could reduce MARCE by approximately 41.5%, 23.6% and 17.2%, respectively, in the T2D population.

conclusionsFour out of five individuals with T2D free from CVRD, and nearly all those with history of CVRD, will develop MARCE over their lifetime. Early preventive measures in T2D patients are clinical, public health and policy priorities.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Heart FailureRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsCohort StudiesHumansRisk FactorsSodium-Glucose Transporter 2 InhibitorsAttributable riskCardiovascularKidneyLifetimePopulation healthType 2 diabetes

Identifiers

PMID35130878
PMCPMC8822817
OpenAlexW4221118309

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.